These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 39427012)

  • 21. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
    Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of Her-2/neu vaccine utilizing idiotypic network cascade.
    Pal S; Saha A; Mohanty K; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Cancer Biol Ther; 2007 Dec; 6(12):1916-25. PubMed ID: 18059165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
    Murthy SK; Magliocco AM; Demetrick DJ
    Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney.
    Huang SS; Huang JS
    J Biol Chem; 1992 Jun; 267(16):11508-12. PubMed ID: 1350785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents.
    Funovics MA; Kapeller B; Hoeller C; Su HS; Kunstfeld R; Puig S; Macfelda K
    Magn Reson Imaging; 2004 Jul; 22(6):843-50. PubMed ID: 15234453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
    Saha A; Chatterjee SK
    Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
    Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
    J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Pakravan N; Hashemi SM; Hassan ZM
    Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
    Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
    Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.
    Daniels TR; Leuchter RK; Quintero R; Helguera G; Rodríguez JA; Martínez-Maza O; Schultes BC; Nicodemus CF; Penichet ML
    Cancer Immunol Immunother; 2012 Jul; 61(7):991-1003. PubMed ID: 22127364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study.
    Kluger HM; DiVito K; Berger AJ; Halaban R; Ariyan S; Camp RL; Rimm DL
    Melanoma Res; 2004 Jun; 14(3):207-10. PubMed ID: 15179190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Her-2/neu and breast cancer.
    Kaptain S; Tan LK; Chen B
    Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.